ZLAB
Zai Lab Ltd
Nasdaq · CIK 1704292
Last close24.33
Daily change-1.17 (-4.59%)
10 Years gain-12.89%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
ZLAB · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
59.5Momentum
99.5Acceleration
96.5Confidence
90.0Annual Revenue8
Quarterly Revenue23
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.9 / 25
Quality15.8 / 25
Capital Efficiency3.5 / 20
Balance Sheet15.0 / 15
Shareholder Economics2.4 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 9.91 percentage points.
ROIC expansionROIC improved by 8.3713 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 4.9709 percentage points.
Key Metrics
Revenue Growth TTM7.85%OK
Revenue CAGR 3Y29.06%OK
Gross Margin58.6%OK
Operating Margin-58.62%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-32.54%OK
Incremental Operating Margin 3Y94.4%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y3.34%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $457.18M | $266.66M | -$229.43M | -$150.79M | -$158.89M | 58.33% | -50.18% | -34.75% | -85.62% | 1.1B |
| 2025 FY Dec 31, 2024 | $397.61M | $250.50M | -$282.12M | -$214.87M | -$220.53M | 63% | -70.95% | -55.46% | -244.1% | 989.48M |
| 2025 FY Dec 31, 2023 | $266.72M | $180.90M | -$366.57M | -$198.18M | -$205.39M | 67.83% | -137.44% | -77.01% | -2,161.78% | 966.39M |
| 2024 FY Dec 31, 2022 | $212.67M | $141.02M | -$404.36M | -$367.64M | -$392.23M | 66.31% | -190.13% | -184.43% | -8,005.06% | 958.07M |
| 2023 FY Dec 31, 2021 | $144.11M | $91.87M | -$700.06M | -$549.23M | -$567.53M | 63.75% | -485.8% | -393.83% | n/a | 929.92M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $425.75M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-053793, 0001704292-25-000024 |
| Revenue Growth TTM | 7.85% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-053793, 0001704292-25-000024 |
| Revenue CAGR 3Y | 29.06% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001704292-26-000015 |
| Revenue CAGR 5Y | 56.33% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001704292-26-000015 |
| Gross Profit CAGR 3Y | 23.66% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001704292-26-000015 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-053793, 0001704292-25-000024 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 58.6% | Gross Profit / Revenue | OK | 0001628280-26-053793, 0001704292-25-000024 |
| Operating Margin | -58.62% | Operating Income / Revenue | OK | 0001628280-26-053793, 0001704292-25-000024 |
| ROIC | -32.54% | NOPAT / Average Invested Capital | OK | 0001628280-26-053793, 0001704292-25-000024 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-053793 |
| Current Ratio | 2.13x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 2.59x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-053793 |
| Revenue per Diluted Share | $0.38 | Revenue / Diluted Shares | OK | 0001628280-26-053793, 0001704292-25-000024 |